Updated recommendations include daraxonrasib for second-line treatment of metastatic pancreatic cancer. This oral multi-selective RAS(ON) inhibitor has demonstrated significant improvements in overall survival and quality of life outcomes.

Source

RELATED ARTICLESMORE FROM AUTHOR